Where does Vidya Therapeutics rank among its competitors?

Vidya Therapeutics ranks 765th amongst 1947 active competitors, of which 100 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Vidya Therapeutics?

Vidya Therapeutics' top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Vidya Therapeutics - 2026 Company Profile & Competitors

Company Details

Developer of oral Bruton tyrosine kinase inhibitor therapies for diseases. Clinical programs focus on treating immune system disorders and central nervous system conditions. The therapy candidate targets cellular pathways to address patient needs in immunology and neurology indications. Development activities include preclinical and clinical testing phases to evaluate safety and efficacy across several conditions.

Key Metrics

Stage

Acquired

Ranked

765^th among 1947 active competitors

Similar Companies

AbbVie & 1975 more

Exit Details

Acquired by Processa (Jul 29, 2026)

View Vidya Therapeutics' full profile

Vidya Therapeutics got acquired by Processa on Jul 29, 2026.

Click here to take a look at Vidya Therapeutics's acquisition in detail

Vidya Therapeutics has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vidya Therapeutics include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Vidya Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 10 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	71/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	68/100
765th	Vidya Therapeutics Acquired	Developer of oral Bruton tyrosine kinase inhibitor therapies for diseases	-	-	20/100